| Document |
Document Title |
|
WO/2023/275195A2 |
Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising • a chelate-functionalized GRP receptor targeting co...
|
|
WO/2023/273416A1 |
The present application relates to an organic compound, an organic electroluminescent device using same, and an electronic apparatus. The organic compound has a structure obtained by fusing formula (1) with one or two Ar groups. The Ar g...
|
|
WO/2023/273356A1 |
The present invention relates to the technical field of organic electroluminescence. Disclosed are a compound containing carbazole and a carbazole derivative, and an organic electroluminescent device. The structural formula of the compou...
|
|
WO/2022/271677A1 |
The application relates to diacylglycerol kinase modulating quinazolin-2-one derivatives of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV ...
|
|
WO/2022/269350A1 |
The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use...
|
|
WO/2022/263619A1 |
The present invention relates to a vinyl keto ester and intermediates of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediates is partly or fully deuterated. Furthermore, the present invention relate...
|
|
WO/2022/263594A1 |
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on bo...
|
|
WO/2022/263472A1 |
Disclosed are compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. Also disclosed are methods of using such compounds as inhibitors of LRRK2, and pharmaceutical compositions compr...
|
|
WO/2022/263620A1 |
The present invention relates to a method for preparing a compound suitable for signal enhanced magnetic resonance imaging comprising the steps of vinylating a mono-, di- or tricarboxylic acid comprising a moiety -Q-Z with Q being O or N...
|
|
WO/2022/260483A1 |
The 18F-ApoPep-7 of chemical formula 1 according to the present invention, which is a derivative of 18F-ApoPep-1, has the manufacturing advantage of labeling the radioisotope F-18 with high radiochemical yield, radiochemical purify, and ...
|
|
WO/2022/253785A2 |
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to...
|
|
WO/2022/253776A1 |
The present invention relates to a method for preparing a radioactive polymerizable solution and the solution per se. The solution is prepared by using a cationic radionuclide with a half-life > 5 d that is dissolved in an aqueous soluti...
|
|
WO/2022/251496A1 |
The present technology provides compounds, as well as compositions including such compounds, useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing e.g., a glypican-3 (GPC3) receptor and/or prostate specific mem...
|
|
WO/2022/243285A1 |
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 rec...
|
|
WO/2022/238553A1 |
Provided are novel SST receptor ligand compounds suitable for the imaging and/or the treatment of neuroendocrine tumors. These SST receptor ligand compounds are comprised of a SST binding motif, a silicon-fluoride acceptor group which ca...
|
|
WO/2022/237889A1 |
A pharmaceutical composition. The pharmaceutical composition comprises N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyri
midin-2-yl)amino)-4-methoxy-2-(methyl(2-(methyl(methyl-d3)am
ino)ethyl)amino)phenyl)acetamide or a pharma...
|
|
WO/2022/226299A1 |
The present disclosure relates to methods of treating a subject having cancer with an 225Ac-radiopharmaceutical, which comprises 225Ac chelated with a compound of Formula (I) wherein the compound binds to neurotensin receptor 1 (NTSR1) a...
|
|
WO/2022/218247A1 |
Provided are a deuterated compound as a CDK4/6 inhibitor, a preparation method therefor, a pharmaceutical composition comprising a deuterated compound, and a use thereof. Compared with a non-deuterated reference compound, the present inv...
|
|
WO/2022/214045A1 |
The present application provides a method for preparing a deuterated chemical by means of a deuteration reaction of a carbon-hydrogen bond with a deuterium gas under the catalysis of an alkali, wherein in the presence of a catalyst, a de...
|
|
WO/2022/216975A1 |
Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co- crystals, metabolites, and prodrugs thereof, and compositio...
|
|
WO/2022/213854A1 |
The present invention relates to a series of carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I). The present carbazole derivative has high stability and triplet energy le...
|
|
WO/2022/206493A1 |
The present application belongs to the technical field of organic electroluminescence and relates to an organic compound, an electronic element comprising said organic compound, and an electronic apparatus. A structure of the organic com...
|
|
WO/2022/212246A1 |
Multi-enzyme systems attached to nanoparticles are effective to efficiently and controllably incorporate stable isotopes (such as deuterium) during the synthesis of small molecules. In one example, deuterium is incorporated into (+)-dihy...
|
|
WO/2022/204417A1 |
Theranostic radiopharmaceutical compositions and methods for targeted infectious disease diagnosis and treatment are provided. The theranostic radiopharmaceutical compositions may include a conjugate of a nucleoside analog, a chelator, a...
|
|
WO/2022/200859A1 |
The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use...
|
|
WO/2022/202956A1 |
Provided is a method by which a stably radiolabeled tyrosine derivative having a good purity can be produced in a safe manner suitable for the industrial production of pharmaceuticals. The present invention pertains to a method for pro...
|
|
WO/2022/195011A1 |
The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and...
|
|
WO/2022/189304A2 |
Up ontil now, only low reactivity Tzs can be radiolabeled via direct aliphatic SN2. Unfortunately, these structures display too low reactivity for in vivo bioorthogonal chemistry approaches. Highly reactive structures such as mono-unsubs...
|
|
WO/2022/186273A1 |
A purpose of the present invention is to provide a novel radioactive compound, in particular a radioactive compound having high biostability. The present invention relates to a radioactive compound represented by formula (I) or a pharm...
|
|
WO/2022/182839A1 |
The present application provides spirocyclic lactam compounds of Formula I that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2022/182731A1 |
Provided herein, in some embodiments, are methods of producing radiolabeled Hsp90 inhibitors and precursors thereof, including tin (Sn)-labeled precursors.
|
|
WO/2022/167057A1 |
The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention a...
|
|
WO/2022/167471A1 |
The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention a...
|
|
WO/2022/169948A1 |
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
|
|
WO/2022/169218A1 |
The present specification pertains to: a method for preparing a deuterated anthracene compound, the method comprising a step of reacting a halogenated benzene having at least one deuterium with enolate to synthesize a deuterated anthrace...
|
|
WO/2022/160390A1 |
Disclosed are a method for preparing deuterium gas and a deuteration reaction using same as a deuterium source. The method for preparing deuterium gas comprises the following steps: dissolving aluminum into liquid metal gallium to obtain...
|
|
WO/2022/161897A1 |
The present invention relates to a method for purifying radiolabelled human serum albumin macroaggregates (MAA) in a solution that can be injected into a patient using a syringe filter, characterized in that the syringe filter used has t...
|
|
WO/2022/161967A1 |
The invention regards a method for 18F-labeling of a peptide.
|
|
WO/2022/157119A1 |
The invention relates to a PSMA-targeting conjugate or a pharmaceutically acceptable salt which may be used either for preparing a radiopharmaceutical or, once labeled with a radionuclide, as a radiopharmaceutical. The conjugate is of fo...
|
|
WO/2022/135327A1 |
The present disclosure provides a compound of general formula (I) or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein C is a chelating agent unit, AB is an albumin binding unit, and FAPI is a fibroblast-activa...
|
|
WO/2022/135072A1 |
Provided in the present invention are a coumarin compound, a preparation method therefor, and the use and a pharmaceutical composition thereof, belonging to the technical field of medicines. The coumarin compound provided in the present ...
|
|
WO/2022/138748A1 |
The present invention provides a labeling method that comprises a step for labeling a substrate, which has a carbon-hydrogen bond, with an oxygen isotope with use of a catalyst and an oxidant that is produced from a hypervalent iodine co...
|
|
WO/2022/134613A1 |
The present application relates to the technical field of organic electroluminescence, and provides a nitrogen-containing compound, an electronic component comprising same, and an electronic apparatus. In the compound of the present appl...
|
|
WO/2022/132924A1 |
The present invention provides novel compounds: (I), and (II) methods of making such compounds, methods of using such compounds for pretargeted imaging, and preparations of formulations for such use.
|
|
WO/2022/123462A1 |
The present disclosure is related to a compound of Formula 1 Wherein R is H or an effector domain which optionally comprises a linker.
|
|
WO/2022/114333A1 |
Disclosed is a method for producing of 2-[18F]fluoro-4-boronophenylalanine comprising radioisotopes ([18F]FBPA), the method having a precursor with an effective leaving group and reaction conditions for high-yield synthesis of [18F]FBPA ...
|
|
WO/2022/106714A1 |
The present invention relates to the radiolabelled compound of enantiomer (R, R) of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphth
alen-2-ol, as well as said compound for use in a method for in-vivo diagnosis of, in particu...
|
|
WO/2022/098584A1 |
A method of purifying radiochemical species (e.g., radiopharmaceuticals) using thin layer chromatography (TLC) plates includes loading one or more TLC plates with a sample containing the radiochemical species to be purified. The one or m...
|
|
WO/2022/098847A1 |
Disclosed herein are compounds related to tolcapone and its metabolite, 3-OMT, along with 3-deoxytolcapone, as well as pharmaceutical compositions comprising the same. Also disclosed are methods of using such compounds and compositions, ...
|
|
WO/2022/098743A1 |
The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The appl...
|
